Search research articles
Contact Us
Filters
Showing results (1-10 of 63) with videos related to
Page
of 7
Sort By:
Drug Design and Discovery
|
January 1, 1993
The development of dopamine D2-receptor selective antagonists
T Högberg
Annals of Medicine
|
February 1, 1995
Primary surgery in ovarian cancer: current opinions
T Högberg
Lakartidningen
|
June 26, 1998
[A new therapeutic program in advanced ovarian cancer. Good results with decentralized cytostatic therapy]
E Henic, T Högberg
Acta Pharmaceutica Nordica
|
January 1, 1992
A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type
U Norinder, T Högberg
Acta Chemica Scandinavica (Copenhagen, Denmark : 1989)
|
April 1, 1992
PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design
U Norinder, T Högberg
Gynecologic Oncology
|
August 1, 1992
Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125
T Högberg, B Kågedal
Acta Pharmaceutica Nordica
|
January 1, 1992
Molecular and crystal structure of the hydrochloride monohydrate of (R)-N-[[1-(4-fluorobenzyl)-2-pyrrolidinyl]methyl]-5-bromo-2,3- dimethoxybenzamide, NCQ 115, a novel dopamine D2 receptor antagonist
I Csöregh, T Högberg
Acta Obstetricia Et Gynecologica Scandinavica
|
January 1, 1990
Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma
T Högberg, B Kågedal
Gynecologic Oncology
|
January 1, 1993
Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer
T Högberg, J Carstensen, E Simonsen
Acta Oncologica (Stockholm, Sweden)
|
July 10, 2001
A systematic overview of chemotherapy effects in ovarian cancer
T Högberg, B Glimelius, P Nygren, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 63) with videos related to
Sort By:
Page
of 7
Drug Design and Discovery
|
January 1, 1993
The development of dopamine D2-receptor selective antagonists
T Högberg
Annals of Medicine
|
February 1, 1995
Primary surgery in ovarian cancer: current opinions
T Högberg
Lakartidningen
|
June 26, 1998
[A new therapeutic program in advanced ovarian cancer. Good results with decentralized cytostatic therapy]
E Henic, T Högberg
Acta Pharmaceutica Nordica
|
January 1, 1992
A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type
U Norinder, T Högberg
Acta Chemica Scandinavica (Copenhagen, Denmark : 1989)
|
April 1, 1992
PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design
U Norinder, T Högberg
Gynecologic Oncology
|
August 1, 1992
Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125
T Högberg, B Kågedal
Acta Pharmaceutica Nordica
|
January 1, 1992
Molecular and crystal structure of the hydrochloride monohydrate of (R)-N-[[1-(4-fluorobenzyl)-2-pyrrolidinyl]methyl]-5-bromo-2,3- dimethoxybenzamide, NCQ 115, a novel dopamine D2 receptor antagonist
I Csöregh, T Högberg
Acta Obstetricia Et Gynecologica Scandinavica
|
January 1, 1990
Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma
T Högberg, B Kågedal
Gynecologic Oncology
|
January 1, 1993
Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer
T Högberg, J Carstensen, E Simonsen
Acta Oncologica (Stockholm, Sweden)
|
July 10, 2001
A systematic overview of chemotherapy effects in ovarian cancer
T Högberg, B Glimelius, P Nygren, et al.
Page
of 7